Kansas State University, 1800 Denison Ave., Mosier Hall, Manhattan, KS66506, USA.
Anim Health Res Rev. 2020 Dec;21(2):177-178. doi: 10.1017/S1466252320000122. Epub 2020 Dec 2.
Bovine respiratory disease (BRD) is one of the most common indications for antimicrobial therapy in beef cattle production and research trials demonstrate that antibiotic therapy greatly improves clinical outcome for BRD. These trials also show that BRD treatment success rates are less than 100% and that there are opportunities to optimize antimicrobial prescribing and improve clinical outcomes if the underlying cause(s) of BRD treatment failures can be identified and addressed. As the etiology of BRD in an individual animal is frequently multi-factorial in nature; it is likely that BRD treatment failures also result from complex interactions between the drug, drug administrator, animal host, pathogens, and the environment. This review will focus specifically on the pharmacological aspects, specifically the interactions between the host and the drug and the drug and the drug administrator, of BRD treatment failures and the actions that veterinary practitioners can take to investigate and mitigate therapeutic failures in future cases.
牛呼吸道疾病(BRD)是肉牛生产中最常见的抗生素治疗指征之一,研究表明抗生素治疗可极大地改善 BRD 的临床结果。这些试验还表明,BRD 的治疗成功率不到 100%,如果能够确定和解决 BRD 治疗失败的根本原因,就有机会优化抗生素的使用并改善临床结果。由于个体动物的 BRD 病因通常是多因素的,因此 BRD 治疗失败也可能是由于药物、药物管理者、动物宿主、病原体和环境之间的复杂相互作用所致。本综述将专门关注 BRD 治疗失败的药理学方面,特别是宿主与药物以及药物与药物管理者之间的相互作用,以及兽医从业者可以采取的行动,以调查和减轻未来病例中的治疗失败。